New oral agent may improve painful IC symptoms

Shiga, Japan-The improvement of interstitial cystitis symptoms with a still-investigational oral agent correlates well with a reduction in bladder platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) expression, suggesting the agent's potential for treating symptoms in patients with nonulcerative IC.

Related Videos

Oral testosterone undecanoate shows promising results for first use in the real world

Related Content

Advertisement

April 1st 2021

Pivotal data for lumasiran in PH1 published in NEJM

Jason M. Broderick

The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.

February 26th 2021

Nedosiran explored in primary hyperoxaluria type 3

Jason M. Broderick

The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria.

February 9th 2021

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

Jason M. Broderick

FDA new drug application filing expected by the end of 2021.

September 12th 2012

FDA approves androgen inhibitor for metastatic PCa

The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).

August 29th 2012

Blood test could guide treatment for kidney cancer

A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to physicians at Duke Cancer Institute, Durham, NC.

August 22nd 2012

BCG for bladder cancer in short supply

Due to manufacturing issues, a formulation of the bladder cancer treatment bacillus Calmette-Guérin is currently unavailable from one manufacturer.

Related Content

Drug Therapy

Drug Therapy

Advertisement

April 1st 2021

Pivotal data for lumasiran in PH1 published in NEJM

Jason M. Broderick

The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.

February 26th 2021

Nedosiran explored in primary hyperoxaluria type 3

Jason M. Broderick

The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria.

February 9th 2021

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

Jason M. Broderick

FDA new drug application filing expected by the end of 2021.

September 12th 2012

FDA approves androgen inhibitor for metastatic PCa

The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).

August 29th 2012

Blood test could guide treatment for kidney cancer

A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to physicians at Duke Cancer Institute, Durham, NC.

August 22nd 2012

BCG for bladder cancer in short supply

Due to manufacturing issues, a formulation of the bladder cancer treatment bacillus Calmette-Guérin is currently unavailable from one manufacturer.